Compounds > 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol
Page last updated: 2024-11-11

6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol: a specific glutathione S-transferase inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9817686
CHEMBL ID1234570
SCHEMBL ID761344
MeSH IDM0520927

Synonyms (19)

Synonym
bdbm50038325
chembl1234570 ,
N11 ,
6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]hexan-1-ol
6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol
nbdhex
3GUS
3IE3
SCHEMBL761344
6-(7-nitrobenzo[c][1,2,5] oxadiazol-4-ylthio)hexan-1-ol
RGXYYAZGELLKDA-UHFFFAOYSA-N
Q27463644
TQP1017
6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)hexan-1-ol
HY-135318
CS-0111351
787634-60-0
MS-24264
AKOS040733830

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The 6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)hexan-1-ol (NBDHEX, 1), a "suicide inhibitor" of the glutathione-S-transferase GSTP1-1, showed pro-apoptotic properties in tumor cells, but in vivo studies were limited by poor bioavailability and high affinity towards GSTM2-2, expressed in many non-cancerous tissues."( Synthesis and structure--activity relationship of new cytotoxic agents targeting human glutathione-S-transferases.
Caccuri, AM; De Luca, A; Falconi, M; Forgione, M; Mai, A; Morozzo Della Rocca, B; Pezzola, S; Rotili, D; Tarantino, D, 2015)		0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutathione S-transferase PHomo sapiens (human)IC50 (µMol)1.13000.05121.70194.0000AID1174247; AID1731076
Glutathione S-transferase PHomo sapiens (human)Ki1.85001.85001.85001.8500AID1731085
Glutathione S-transferase Mu 2Homo sapiens (human)IC50 (µMol)0.01500.01000.01500.0200AID1174248; AID1731077
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Glutathione S-transferase PHomo sapiens (human)Kd0.55500.21000.55500.9000AID977611
Chain A, Glutathione S-transferase PHomo sapiens (human)Kd0.55500.21000.55500.9000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (43)

Processvia Protein(s)Taxonomy
response to reactive oxygen speciesGlutathione S-transferase PHomo sapiens (human)
negative regulation of acute inflammatory responseGlutathione S-transferase PHomo sapiens (human)
negative regulation of protein kinase activityGlutathione S-transferase PHomo sapiens (human)
prostaglandin metabolic processGlutathione S-transferase PHomo sapiens (human)
glutathione metabolic processGlutathione S-transferase PHomo sapiens (human)
xenobiotic metabolic processGlutathione S-transferase PHomo sapiens (human)
central nervous system developmentGlutathione S-transferase PHomo sapiens (human)
negative regulation of biosynthetic processGlutathione S-transferase PHomo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathwayGlutathione S-transferase PHomo sapiens (human)
negative regulation of interleukin-1 beta productionGlutathione S-transferase PHomo sapiens (human)
negative regulation of tumor necrosis factor productionGlutathione S-transferase PHomo sapiens (human)
regulation of stress-activated MAPK cascadeGlutathione S-transferase PHomo sapiens (human)
negative regulation of stress-activated MAPK cascadeGlutathione S-transferase PHomo sapiens (human)
positive regulation of superoxide anion generationGlutathione S-transferase PHomo sapiens (human)
common myeloid progenitor cell proliferationGlutathione S-transferase PHomo sapiens (human)
nitric oxide storageGlutathione S-transferase PHomo sapiens (human)
negative regulation of apoptotic processGlutathione S-transferase PHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionGlutathione S-transferase PHomo sapiens (human)
negative regulation of MAP kinase activityGlutathione S-transferase PHomo sapiens (human)
negative regulation of MAPK cascadeGlutathione S-transferase PHomo sapiens (human)
negative regulation of JUN kinase activityGlutathione S-transferase PHomo sapiens (human)
linoleic acid metabolic processGlutathione S-transferase PHomo sapiens (human)
negative regulation of fibroblast proliferationGlutathione S-transferase PHomo sapiens (human)
hepoxilin biosynthetic processGlutathione S-transferase PHomo sapiens (human)
negative regulation of nitric-oxide synthase biosynthetic processGlutathione S-transferase PHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeGlutathione S-transferase PHomo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeGlutathione S-transferase PHomo sapiens (human)
negative regulation of leukocyte proliferationGlutathione S-transferase PHomo sapiens (human)
cellular response to lipopolysaccharideGlutathione S-transferase PHomo sapiens (human)
negative regulation of monocyte chemotactic protein-1 productionGlutathione S-transferase PHomo sapiens (human)
cellular oxidant detoxificationGlutathione S-transferase PHomo sapiens (human)
glutathione derivative biosynthetic processGlutathione S-transferase PHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayGlutathione S-transferase PHomo sapiens (human)
glutathione metabolic processGlutathione S-transferase Mu 2Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulumGlutathione S-transferase Mu 2Homo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionGlutathione S-transferase Mu 2Homo sapiens (human)
regulation of skeletal muscle contraction by regulation of release of sequestered calcium ionGlutathione S-transferase Mu 2Homo sapiens (human)
nitrobenzene metabolic processGlutathione S-transferase Mu 2Homo sapiens (human)
xenobiotic catabolic processGlutathione S-transferase Mu 2Homo sapiens (human)
linoleic acid metabolic processGlutathione S-transferase Mu 2Homo sapiens (human)
hepoxilin biosynthetic processGlutathione S-transferase Mu 2Homo sapiens (human)
relaxation of cardiac muscleGlutathione S-transferase Mu 2Homo sapiens (human)
negative regulation of ryanodine-sensitive calcium-release channel activityGlutathione S-transferase Mu 2Homo sapiens (human)
positive regulation of ryanodine-sensitive calcium-release channel activityGlutathione S-transferase Mu 2Homo sapiens (human)
cellular detoxification of nitrogen compoundGlutathione S-transferase Mu 2Homo sapiens (human)
cellular response to caffeineGlutathione S-transferase Mu 2Homo sapiens (human)
cellular oxidant detoxificationGlutathione S-transferase Mu 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
glutathione transferase activityGlutathione S-transferase PHomo sapiens (human)
glutathione peroxidase activityGlutathione S-transferase PHomo sapiens (human)
fatty acid bindingGlutathione S-transferase PHomo sapiens (human)
protein bindingGlutathione S-transferase PHomo sapiens (human)
JUN kinase bindingGlutathione S-transferase PHomo sapiens (human)
kinase regulator activityGlutathione S-transferase PHomo sapiens (human)
S-nitrosoglutathione bindingGlutathione S-transferase PHomo sapiens (human)
dinitrosyl-iron complex bindingGlutathione S-transferase PHomo sapiens (human)
nitric oxide bindingGlutathione S-transferase PHomo sapiens (human)
glutathione transferase activityGlutathione S-transferase Mu 2Homo sapiens (human)
glutathione peroxidase activityGlutathione S-transferase Mu 2Homo sapiens (human)
signaling receptor bindingGlutathione S-transferase Mu 2Homo sapiens (human)
fatty acid bindingGlutathione S-transferase Mu 2Homo sapiens (human)
protein bindingGlutathione S-transferase Mu 2Homo sapiens (human)
enzyme bindingGlutathione S-transferase Mu 2Homo sapiens (human)
protein homodimerization activityGlutathione S-transferase Mu 2Homo sapiens (human)
glutathione bindingGlutathione S-transferase Mu 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
extracellular regionGlutathione S-transferase PHomo sapiens (human)
extracellular spaceGlutathione S-transferase PHomo sapiens (human)
nucleusGlutathione S-transferase PHomo sapiens (human)
cytoplasmGlutathione S-transferase PHomo sapiens (human)
mitochondrionGlutathione S-transferase PHomo sapiens (human)
cytosolGlutathione S-transferase PHomo sapiens (human)
vesicleGlutathione S-transferase PHomo sapiens (human)
secretory granule lumenGlutathione S-transferase PHomo sapiens (human)
extracellular exosomeGlutathione S-transferase PHomo sapiens (human)
ficolin-1-rich granule lumenGlutathione S-transferase PHomo sapiens (human)
TRAF2-GSTP1 complexGlutathione S-transferase PHomo sapiens (human)
cytosolGlutathione S-transferase PHomo sapiens (human)
cytoplasmGlutathione S-transferase Mu 2Homo sapiens (human)
cytosolGlutathione S-transferase Mu 2Homo sapiens (human)
sarcoplasmic reticulumGlutathione S-transferase Mu 2Homo sapiens (human)
intercellular bridgeGlutathione S-transferase Mu 2Homo sapiens (human)
extracellular exosomeGlutathione S-transferase Mu 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (31)

Assay IDTitleYearJournalArticle
AID1731117Antitumor activity against human 143B cells xenografted in BALB/c nude mouse assessed as tumor growth inhibition at 5 mg/kg, po administered once daily for 28 consecutive days relative to control2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Discovery of 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol Derivatives as Glutathione Transferase Inhibitors with Favorable Selectivity and Tolerated Toxicity.
AID1731109Plasma clearance in Sprague-Dawley rat at 80 mg/kg, po administered as single dose measured upto 48 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Discovery of 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol Derivatives as Glutathione Transferase Inhibitors with Favorable Selectivity and Tolerated Toxicity.
AID1731085Time dependent inhibition of GSTP1-1 (unknown origin) assessed as inhibition constant using reduced GSH and CDNB as substrate by spectrophotometric method2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Discovery of 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol Derivatives as Glutathione Transferase Inhibitors with Favorable Selectivity and Tolerated Toxicity.
AID1731091Antiproliferative activity against human HOS cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Discovery of 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol Derivatives as Glutathione Transferase Inhibitors with Favorable Selectivity and Tolerated Toxicity.
AID1731113MRT (0 to t) in Sprague-Dawley rat at 80 mg/kg, po administered as single dose measured upto 48 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Discovery of 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol Derivatives as Glutathione Transferase Inhibitors with Favorable Selectivity and Tolerated Toxicity.
AID1731077Inhibition of GSTM2-2 (unknown origin) using reduced GSH and CDNB as substrate incubated for 10 mins followed by substrate addition by microplate reader analysis2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Discovery of 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol Derivatives as Glutathione Transferase Inhibitors with Favorable Selectivity and Tolerated Toxicity.
AID1174249Selectivity index, ratio of IC50 for GSTP1-1 (unknown origin) to IC50 for GSTM2-3 (unknown origin)2015European journal of medicinal chemistry, Jan-07, Volume: 89Synthesis and structure--activity relationship of new cytotoxic agents targeting human glutathione-S-transferases.
AID1731088Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Discovery of 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol Derivatives as Glutathione Transferase Inhibitors with Favorable Selectivity and Tolerated Toxicity.
AID1174251Cytotoxicity against human U2OS cells assessed as cell survival after 48 hrs SRB assay2015European journal of medicinal chemistry, Jan-07, Volume: 89Synthesis and structure--activity relationship of new cytotoxic agents targeting human glutathione-S-transferases.
AID1743060Antigiardial activity against Giardia duodenalis WBC6 trophozoites incubated for 48 hrs under microaerophilic condition by methylene blue colorimetric assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Anti-
AID1731114MRT (0 to infinity) in Sprague-Dawley rat at 80 mg/kg, po administered as single dose measured upto 48 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Discovery of 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol Derivatives as Glutathione Transferase Inhibitors with Favorable Selectivity and Tolerated Toxicity.
AID1731086Cytotoxicity against HUVEC assessed as reduction in cell viability incubated for 72 hrs by MTT assay2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Discovery of 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol Derivatives as Glutathione Transferase Inhibitors with Favorable Selectivity and Tolerated Toxicity.
AID1174247Inhibition of GSTP1-1 (unknown origin) using GSH substrate by spectrophotometric method2015European journal of medicinal chemistry, Jan-07, Volume: 89Synthesis and structure--activity relationship of new cytotoxic agents targeting human glutathione-S-transferases.
AID1731076Inhibition of GSTP1-1 (unknown origin) using reduced GSH and CDNB as substrate incubated for 10 mins followed by substrate addition by microplate reader analysis2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Discovery of 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol Derivatives as Glutathione Transferase Inhibitors with Favorable Selectivity and Tolerated Toxicity.
AID1731079Water solubility of the compound measured by UV-Visible spectral analysis2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Discovery of 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol Derivatives as Glutathione Transferase Inhibitors with Favorable Selectivity and Tolerated Toxicity.
AID1731112Volume of distribution in Sprague-Dawley rat at 80 mg/kg, po administered as single dose measured upto 48 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Discovery of 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol Derivatives as Glutathione Transferase Inhibitors with Favorable Selectivity and Tolerated Toxicity.
AID1731108Terminal half life in Sprague-Dawley rat at 80 mg/kg, po administered as single dose measured upto 48 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Discovery of 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol Derivatives as Glutathione Transferase Inhibitors with Favorable Selectivity and Tolerated Toxicity.
AID1174252GSH reactivity assessed as spontaneous reactivity at 40 uM at pH 6.5 by UV-visible spectrum analysis in presence of 1 mM GSH2015European journal of medicinal chemistry, Jan-07, Volume: 89Synthesis and structure--activity relationship of new cytotoxic agents targeting human glutathione-S-transferases.
AID1731089Antiproliferative activity against human B16 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Discovery of 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol Derivatives as Glutathione Transferase Inhibitors with Favorable Selectivity and Tolerated Toxicity.
AID1731106Tmax in Sprague-Dawley rat at 80 mg/kg, po administered as single dose measured upto 48 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Discovery of 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol Derivatives as Glutathione Transferase Inhibitors with Favorable Selectivity and Tolerated Toxicity.
AID1731087Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Discovery of 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol Derivatives as Glutathione Transferase Inhibitors with Favorable Selectivity and Tolerated Toxicity.
AID1174248Inhibition of GSTM2-2 (unknown origin) using GSH substrate by spectrophotometric method2015European journal of medicinal chemistry, Jan-07, Volume: 89Synthesis and structure--activity relationship of new cytotoxic agents targeting human glutathione-S-transferases.
AID1731084Time dependent inhibition of GSTP1-1 (unknown origin) assessed as Kinact at 0.1 to 5 uM using reduced GSH and CDNB as substrate by spectrophotometric method2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Discovery of 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol Derivatives as Glutathione Transferase Inhibitors with Favorable Selectivity and Tolerated Toxicity.
AID1731078Selectivity index, ratio of IC50 for GSTP1-1 (unknown origin) to IC50 for GSTM2-2 (unknown origin)2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Discovery of 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol Derivatives as Glutathione Transferase Inhibitors with Favorable Selectivity and Tolerated Toxicity.
AID1731110AUC (0 to t) in Sprague-Dawley rat at 80 mg/kg, po administered as single dose measured upto 48 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Discovery of 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol Derivatives as Glutathione Transferase Inhibitors with Favorable Selectivity and Tolerated Toxicity.
AID1731107Cmax in Sprague-Dawley rat at 80 mg/kg, po administered as single dose measured upto 48 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Discovery of 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol Derivatives as Glutathione Transferase Inhibitors with Favorable Selectivity and Tolerated Toxicity.
AID1743054Antigiardial activity against Giardia duodenalis WBC6 trophozoites incubated for 72 hrs under anaerobic condition by resazurin-dye based fluorimetry2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Anti-
AID1731111AUC (0 to infinity) in Sprague-Dawley rat at 80 mg/kg, po administered as single dose measured upto 48 hrs by LC-MS/MS analysis2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Discovery of 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol Derivatives as Glutathione Transferase Inhibitors with Favorable Selectivity and Tolerated Toxicity.
AID1174250Solubility in water2015European journal of medicinal chemistry, Jan-07, Volume: 89Synthesis and structure--activity relationship of new cytotoxic agents targeting human glutathione-S-transferases.
AID1731090Antiproliferative activity against human 143B cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Discovery of 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol Derivatives as Glutathione Transferase Inhibitors with Favorable Selectivity and Tolerated Toxicity.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2009Cancer research, Oct-15, Volume: 69, Issue:20
Structural basis for the binding of the anticancer compound 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol to human glutathione s-transferases.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (25.00)29.6817
2010's16 (66.67)24.3611
2020's2 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.69 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
kynurenine
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.. kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.		2.2110aromatic ketone;
non-proteinogenic alpha-amino acid;
substituted aniline		human metabolite
albendazole
[no description available]		3.3510aryl sulfide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester		anthelminthic drug;
microtubule-destabilising agent;
tubulin modulator
benzyl isothiocyanate
benzyl isothiocyanate: inhibits carcinogen-induced neoplasia; structure in Negwer, 5th ed, #715; also promotes urinary bladder carcinoma		2.1710benzenes;
isothiocyanate		antibacterial drug
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		2.2110aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
disulfiram
[no description available]		3.3510organic disulfide;
organosulfur acaricide		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 3.1.1.1 (carboxylesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
ferroptosis inducer;
fungicide;
NF-kappaB inhibitor
erythrosine
Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.		2.1710
mebendazole
Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.		3.3510aromatic ketone;
benzimidazoles;
carbamate ester		antinematodal drug;
microtubule-destabilising agent;
tubulin modulator
metronidazole
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.		3.3510C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic
omeprazole
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.		3.3510aromatic ether;
benzimidazoles;
pyridines;
sulfoxide
temozolomide
[no description available]		7.0610imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug
tinidazole
Tinidazole: A nitroimidazole alkylating agent that is used as an antitrichomonal agent against TRICHOMONAS VAGINALIS; ENTAMOEBA HISTOLYTICA; and GIARDIA LAMBLIA infections. It also acts as an antibacterial agent for the treatment of BACTERIAL VAGINOSIS and anaerobic bacterial infections.. tinidazole : 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent.		3.3510imidazolesantiamoebic agent;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug
benzimidazole
1H-benzimidazole : The 1H-tautomer of benzimidazole.		3.3510benzimidazole;
polycyclic heteroarene
1-hexanol
1-hexanol: RN given refers to parent cpd. hexanol : A fatty alcohol consisting of a hydroxy function at any position of an unbranched saturated chain of six carbon atoms.. hexan-1-ol : A primary alcohol that is hexane substituted by a hydroxy group at position 1.		3.5920hexanol;
primary alcohol		alarm pheromone;
antibacterial agent;
fragrance;
plant metabolite
carbendazim
carbendazim: carcinogen when combined with sodium nitrite; principle metabolite of thiophanate methyl & benomyl; structure. carbendazim : A member of the class of benzimidazoles that is 2-aminobenzimidazole in which the primary amino group is substituted by a methoxycarbonyl group. A fungicide, carbendazim controls Ascomycetes, Fungi Imperfecti, and Basidiomycetes on a wide variety of crops, including bananas, cereals, cotton, fruits, grapes, mushrooms, ornamentals, peanuts, sugarbeet, soybeans, tobacco, and vegetables.		3.3510benzimidazole fungicide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester		antifungal agrochemical;
antinematodal drug;
metabolite;
microtubule-destabilising agent
nitazoxanide
nitazoxanide: a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug		3.3510benzamides;
carboxylic ester
diacetylfluorescein
[no description available]		2.1710
glutathione disulfide
Glutathione Disulfide: A GLUTATHIONE dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.		2.0810glutathione derivative;
organic disulfide		Escherichia coli metabolite;
mouse metabolite
secnidazole
[no description available]		3.3510C-nitro compound;
imidazoles;
secondary alcohol		epitope
methotrexate
[no description available]		2.0610dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
orlistat
Orlistat: A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity.. orlistat : A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.		3.3510beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative		anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor
oxadiazoles
Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.		5.64220
plx4032
[no description available]		2.5520aromatic ketone;
difluorobenzene;
monochlorobenzenes;
pyrrolopyridine;
sulfonamide		antineoplastic agent;
B-Raf inhibitor
dacarbazine
(E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.		2.0610dacarbazine
ConditionIndicatedRelationship StrengthStudiesTrials
Giardia duodenalis Infection
[description not available]		03.1710
Giardiasis
An infection of the SMALL INTESTINE caused by the flagellated protozoan GIARDIA. It is spread via contaminated food and water and by direct person-to-person contact.		03.1710
Hepatocellular Carcinoma
[description not available]		02.2110
Cancer of Liver
[description not available]		02.2110
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.2110
Liver Neoplasms
Tumors or cancer of the LIVER.		02.2110
Malignant Melanoma
[description not available]		08.0140
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		03.0140
Benign Neoplasms
[description not available]		03.0910
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.0910
Carcinoma, Non-Small Cell Lung
[description not available]		02.2110
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		02.2110
Osteogenic Sarcoma
[description not available]		02.7730
Osteosarcoma
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)		02.7730
Bone Cancer
[description not available]		02.7430
Bone Neoplasms
Tumors or cancer located in bone tissue or specific BONES.		02.7430
Acute Myelogenous Leukemia
[description not available]		02.0510
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		02.4520
Leukemia, Myeloid, Acute
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.		02.0510
Ewing Sarcoma
[description not available]		02.0510
Sarcoma, Ewing
A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females.		02.0510
B16 Melanoma
[description not available]		02.0610
Sarcoma, Epithelioid
[description not available]		02.0610
Cancer of Muscle
[description not available]		02.0610
Sarcoma
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.		02.0610
Neoplasms, Pleural
[description not available]		02.0810
Mesothelioma
A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)		02.0810
Carcinoma, Oat Cell
[description not available]		02.0410
Cancer of Lung
[description not available]		02.0410
Lung Neoplasms
Tumors or cancer of the LUNG.		02.0410
Carcinoma, Small Cell
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)		02.0410